Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-SOST Antibody, Non-Fucosylated (BioBet-445ZP) (CAT#: BioBet-445ZP) Datasheet

Target
SOST
Isotype
IgG4, κ
Description
Anti-SOST Antibody, Non-Fucosylated (BioBet-445ZP) is a humanized monoclonal IgG4, κ antibody against SOST. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Postmenopausal women osteoporosis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced SOST antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SOST
Full Name
Sclerostin
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]
Alternative Names
Blosozumab; 1132758-87-2; LY2541546; SOST; sclerostin; sclerosteosis; VBCH;
Gene ID
50964
UniProt ID
Q9BQB4
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with SOST include Sclerosteosis 1 and Craniodiaphyseal Dysplasia, Autosomal Dominant.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
Field of research
Developmental Biology antibody; Signaling Transduction antibody
Post-translational modifications
Glycosylation at Asn53 and Asn175
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4, κ
Antibody Clone
BioBet-445ZP
Host
Humanized
Species Reactivity
Human
Description
ADCC-enhanced Blosozumab is a non-fucosylated anti-SOST therapeutic biobetter antibody.
Antibody Indication
Postmenopausal women osteoporosis

Postmenopausal women osteoporosis

Related Products

Anti-SOST Antibody, On-Target (AES-0622-ZP706) (CAT#: AES-0622-ZP706)
Anti-SOST Antibody, Highly Galactosylated (BioBet-GA-446ZP) (CAT#: BioBet-GA-446ZP)
Anti-SOST Antibody, Recycling (AES-0622-ZP50) (CAT#: AES-0622-ZP50)
Anti-SOST Antibody, Half-Life Extended (AES-0622-ZP1034) (CAT#: AES-0622-ZP1034)
Anti-SOST Antibody, Highly Galactosylated (BioBet-GA-445ZP) (CAT#: BioBet-GA-445ZP)
Anti-SOST Antibody, Non-Fucosylated (BioBet-446ZP) (CAT#: BioBet-446ZP)
Anti-SOST Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP378) (CAT#: AES-0622-ZP378)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas